The therapeutic versatility of peptide decoys extends beyond the scope of our study, with existing proposals advocating their application in cancer treatment strategies involving host cell surface receptors, exemplified by Human Epidermal Growth Factor 2 (HER2) in breast cancer [61]. This evidence concerns the gene CD177 and breast carcinoma.